Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile

Journal of the American College of Cardiology

Volumn 33, Issue 5, 1999, Pages 1294-1304

  Dangas, George ^a,c   Badimon, Juan J ^b   Smith, Donald A ^a   Unger, Allen H ^c   Levine, Daniel ^a   Shao, John H ^c   Meraj, Perwaiz ^a   Fier, Carl ^a   Fallon, John T ^a   Ambrose, John A ^b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOGENESIS; THROMBUS;

AGED; ASPIRIN; BLOOD COAGULATION FACTORS; CHOLESTEROL, LDL; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033117022     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00018-2     Document Type: Article

References (55)

1. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256:2835-8.
2. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
3. Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
4. Lipid Research Clinic Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: 1. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
5. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
6. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC 1). Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26: 1133-9.
7. Jukema JW, Bruschke AV, van Bowen AJ, et al. Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated cholesterol levels. The Regression Growth Evaluation Statin Study. (REGRESS). Circulation 1995;91:2528-40.
8. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
9. Blankenhorn DH, Azen SP, Kramsch DM, et al. (MARS Research Group). Coronary angiographie changes with lovastatin therapy: the Monitored Atherosclerosis progression Study (MARS). Ann Intern Med 1993;119:969-76.
10. Waters D, Higginson L, Gladstone P, et al. (CCAIT Study Group). Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
11. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
12. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92:2419-25.
13. Ambrose JA, Winters SI, Stern A, et al. Angiographie morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985;5:609-16.
14. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. Circulation 1996;94:2013-20.
15. El Fawal MA, Berg GA, Wheatley DJ, Harland WA. Sudden coronary death in Glasgow: nature and frequency of acute coronary lesions. Br Heart J 1987;57:329-35.
16. Femandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implication for consequences of plaque rupture. J Am Coll Cardiol 1996;23:1562-9.
17. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93: 1354-63.
18. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-8.
19. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
20. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
21. Meade TW, Brozovic M, Chakrabarti RR, et al. Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986:533-7.
22. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995;91:2520-7.
23. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
24. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering, and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
25. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endotheliumdependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-1500.
26. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-7.
27. Wada H, Mori Y, Kaneko T, et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993;44:112-6.
28. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993;70:241-3.
29. 1+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost 1992;67:503-6.
30. Simpson IA, Lorimer R, Walker ID, Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolemia. Thromb Haemost 198S;54:442-4.
31. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 1962;27:645-8.
32. Badimon L, Turitto V, Rosemark JA, Badimon JJ, Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium-111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987;110:706-18.
33. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantification of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993;81:734-44.
34. Mailhac A, Badimon JJ, Fallon JT, et al. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: relative contribution of fibrin(ogen) and platelets. Circulation 1994;90:988-96.
35. Dangas G, Badimon JJ, Coller BS, et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition under dynamic flow conditions: implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vase Biol 1998;18:1342-9.
36. Tsuda Y, Satoh K, Kitadi M. Effects of prevastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996;122: 225-33.
37. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet 1998;351:569-70.
38. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324-8.
39. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endotheliumdependent, coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
40. Vanderkerchove Y, Baele G, dePuydt H, Weyne A, Clement D. Plasma tissue plasminogen activator levels in patients with coronary heart disease. Thromb Res 1988;50:449-53.
41. Ridker PM, Vaughn DE, Stampfer MJ. Baseline fibrinolytic state and the risk of future venous thrombosis: a prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992;85:1822-7.
42. Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-I levels on the molar concentration of active tissue plasminogen activator (tPA) and tPA/PAI-I complex in plasma. Blood 1990;76:930-7.
43. Hamsten A. Hemostatic function and coronary disease. N Engl J Med 1991;332:677-8.
44. Ambrose JA, Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med 1996;156:1382-94.
45. Willerson JT, Golino P, Eidt J, Campbell WB, Buja M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989;80:198-205.
46. Carvalho ACA, Colman RW, Lees RS. Platelet function in hyperlipoprotenemia. N Engl J Med 1974;290:434-8.
47. Davis G, Averna M, Catalano L, et al. Increased thromboxane biosynthesis in type Ha hypercholesterolemia. Circulation 1992;85:1792-8.
48. Antiplatelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-31.
49. Davies MJ, Bland JM, Hangartner JRW, Angelinin A, Thomas AC. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischemic death. Eur Heart J 1989;10:203-8.
50. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? Br Med J 1994;308:367-72.
51. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-7.
52. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5.
53. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998;97:1446-52.
54. Lacoste L, Lam JYT. Comparative effect of pravastatin and simvastatin on platelet thrombus formation in hypercholesterolemic coronary patients. J Am Coll Cardiol 1996;27 Suppl A:413A.
55. Rauch U, Badimon JJ, Vorchheimer DA, et al. Lipid-lowering therapy reduces blood thrombogenicity in hypercholesterolemic patients: effect of simvastatin. J Am Coll Cardiol 1998;31 Suppl A:194A.